HER2-Positive Breast Cancer

  • ID: 4483058
  • Book
  • 264 Pages
  • Elsevier Health Science
1 of 4

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 4
Background/testing

1. The HER2 alteration in breast cancer

2. HER2 testing in the era of changing guidelines

Advanced Disease

3. Optimal first-line treatment of HER2+ advanced disease

4. Second line therapy and beyond

5. HER2+ CNS metastases

Therapeutics

6. Neoadjuvant therapy

7. Adjuvant therapy

8. Outcomes based on HR status in early stage disease

9. De-escalation of therapy for small tumor

Toxicity considerations

10. Cardiac toxicity of HER2-targeted regimens

11. Non-cardiac toxicity of HER2-targeted therapy

Therapies on the horizon

12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)

13. Harnessing the immune system in HER2+ disease

14. Biosimilars
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Hurvitz, Sara
McCann, Kelly
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll